Abbey Spanier Rodd & Abrams, LLP Commences Class Action Securities Fraud on Behalf of Purchasers of GPC Biotech AG Securities
July 26 2007 - 3:41PM
PR Newswire (US)
NEW YORK, July 26 /PRNewswire/ -- Abbey Spanier Rodd & Abrams,
LLP commenced a Class Action lawsuit in the United States District
Court for the Southern District of New York (Case No. 06-cv-6728)
on behalf of a class (the "Class") of all persons who purchased or
acquired securities of GPC Biotech AG ("GPC Biotech" or the
"Company") (NASDAQ:GPCB) between December 5, 2005 and July 24, 2007
inclusive (the "Class Period"). The Complaint alleges that
defendants violated the anti-fraud provisions of the federal
securities laws, by issuing a series of materially false public
statements during the Class Period thereby artificially inflating
the price of GPC Biotech securities. GPC Biotech had spent years
attempting to successfully develop it key drug Satraplatin, an oral
drug therapy whose goal is to increase overall survival rates,
reduce pain, and produce "progression free survival" for advanced
prostate cancer patients, and needed to convince investors and
collaboration partners who were funding the Company each year that
it was making substantial progress toward Satraplatin's "early" FDA
approval to obtain continued funding. However, unbeknownst to
public investors, the Phase 3 trial that needed to be conducted for
Satraplatin was deeply flawed and employed improper methods for
measuring Satraplatin's efficacy. The defendants knew of these
gross irregularities not only because of their substantial
experience in pharmaceutical development and testing, but also
because (as was revealed at the end of the Class Period) they were
specifically warned by FDA representatives during Satraplatin's
development phase that they were deviating from accepted
methodologies, and that the "endpoint" they had selected was one
with which the FDA was "unfamiliar" and had "no prior experience."
Thus Defendants knew that there was a very substantial chance that
the FDA would not approve the drug. Defendants stayed silent about
the adverse facts regarding Satraplatin and its unapproved endpoint
methodology until they were forced to address them due to FDA
disclosures. On May 15, 2007, the Company announced that the FDA
would consider approval of Satraplatin at a meeting scheduled for
July 24, 2007. On July 24, 2007, the FDA announced that its
oncology panel had unanimously recommended against the approval of
Satraplatin. The committee said the FDA had no prior experience
with that type of endpoint, an issue which was "clearly
communicated" to GPC Biotech while the drug was in development. In
reaction to these unexpected revelations, GPC Biotech stock fell
$7.20 on July 25, 2007 to close at $13.16. Plaintiff seeks to
recover damages on behalf of all those who purchased or otherwise
acquired GPC Biotech securities during the Class Period, December
5, 2005 and July 24, 2007. If you purchased or otherwise acquired
GPC Biotech securities during the Class Period, and either lost
money on the transaction or still hold the securities, you may wish
to join in the action to serve as lead plaintiff. If you purchased
GPC Biotech securities during the Class Period, you may, no later
than 60 days from today request that the Court appoint you as lead
plaintiff. A lead plaintiff is a representative party that acts on
behalf of other class members in directing the litigation. In order
to be appointed lead plaintiff, the Court must determine that the
class member's claim is typical of the claims of other class
members, and that the class member will adequately represent the
class. Under certain circumstances, one or more class members may
together serve as "lead plaintiffs.' The attorneys Abbey Spanier
Rodd & Abrams, LLP have extensive experience in securities
class action cases, and have played lead roles in major cases
resulting in the recovery of hundreds of billions of dollars to
investors. If you would like to discuss this action or if you have
any questions concerning this Notice or your rights as a potential
class member or lead plaintiff, you may contact: Nancy Kaboolian,
Esq. or Susan Lee Abbey Spanier Rodd & Abrams, LLP 212 East
39th Street New York, New York 10016 (212) 889-3700 (800) 889-3701
(Toll Free) Or e-mail or DATASOURCE: Abbey Spanier Rodd &
Abrams, LLP CONTACT: Nancy Kaboolian, Esq., , or Susan Lee, , both
of Abbey Spanier Rodd & Abrams, LLP, +1-212-889-3700, Toll
Free, +1-800-889-3701 Web site: http://www.abbeygardy.com/
Copyright
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Historical Stock Chart
From May 2024 to Jun 2024
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Historical Stock Chart
From Jun 2023 to Jun 2024